LaserGen | GenomeWeb

LaserGen

The firm's $80 investment in Lasergen sets the stage for it to develop an integrated sample-to-result clinical genomics workflow by 2020.

Agilent said it will work with Lasergen to build a clinical sequencing workflow based on the smaller firm's Lightning Terminators sequencing chemistry.

LaserGen has named Mimi Healy CEO and to its board of directors. She is taking over from founder Michael Metzker, who developed and patented the company's proprietary Lightning Terminators.

By Julia Karow
This article has been updated to include information about Roche/IBM and Genia.

LaserGen has raised $5 million in a Series A financing round, which it will use to demonstrate accurate sequencing of the Escherichia coli genome and to continue developing its next-generation sequencing system.

Last week, the Baylor College of Medicine spinout disclosed that it has teamed up with National Instruments to build and validate a prototype sequencer that uses its "Lightning Terminator" chemistry.

The firms aim to have a system developed and installed at a genome center for validation testing by the end of this year.

Pages

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.